LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Home・Akciju saraksts・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

27.44 3.24

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

27.16

Max

27.44

Galvenie mērījumi
By Trading Economics
Ienākumi	45M 72M
Pārdošana	14M 279M
P/E Sektora vidējais	16.032 80.03
EPS	0.42
Peļņas marža	25.761
Darbinieki	653
EBITDA	7.3M 48M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+13.41% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	430M 4.2B
Iepriekšējā atvēršanas cena	24.2
Iepriekšējā slēgšanas cena	27.44

Ziņu noskaņojums

By Acuity

18%

82%

19 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

14.845 / N/A Atbalsts un pretestība

ACADIA Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 5. dec. 21:08 UTC

Iegādes, apvienošanās, pārņemšana

Meta Platforms Buys AI-Device Maker Limitless

2025. g. 5. dec. 19:39 UTC

Galvenie tirgus virzītāji

Parsons' FAA Bid Loss Clouds Outlook After Rocky Year for Contractors

2025. g. 5. dec. 19:17 UTC

Iegādes, apvienošanās, pārņemšana

Constellation Energy Agrees to Divest Assets to Finalize Calpine Deal

2025. g. 6. dec. 16:52 UTC

Iegādes, apvienošanās, pārņemšana

As Netflix Swoops In to Buy Warner Bros., We Revisit the Studio's Long, Twisted Journey -- Barrons.com

2025. g. 6. dec. 10:30 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Why Netflix Shareholders Aren't Thrilled to Acquire Warner Bros. -- Heard on the Street -- WSJ

2025. g. 6. dec. 02:38 UTC

Iegādes, apvienošanās, pārņemšana

How a Netflix-Warner Deal Would Change Everything in Hollywood -- Again -- WSJ

2025. g. 5. dec. 21:59 UTC

Iegādes, apvienošanās, pārņemšana

Netflix's Megadeal Will Need the Trump Administration's Blessing -- Update

2025. g. 5. dec. 21:50 UTC

Tirgus saruna

Peļņas

Financial Services Roundup: Market Talk

2025. g. 5. dec. 21:50 UTC

Iegādes, apvienošanās, pārņemšana

The Netflix and Warner Bros. Deal Is Far From a Sure Thing -- Barrons.com

2025. g. 5. dec. 21:36 UTC

Tirgus saruna

Return of Shipping to Red Sea a Step Closer, Xeneta Says -- Market Talk

2025. g. 5. dec. 21:35 UTC

Iegādes, apvienošanās, pārņemšana

The Netflix-Warner Bros. Deal Has a Wildcard. How Paramount Could Still Win. -- Barrons.com

2025. g. 5. dec. 21:26 UTC

Iegādes, apvienošanās, pārņemšana

Warner Bros. Discovery and Netflix Enter Exclusive Deal Negotiations -- 7th Update

2025. g. 5. dec. 21:12 UTC

Tirgus saruna

Natural Gas Surge 9% This Week on Strong Flow of Exports -- Market Talk

2025. g. 5. dec. 21:03 UTC

Tirgus saruna

Peļņas

Bank of Montreal Logs Solid Quarter, Though Some Unease Remains -- Market Talk

2025. g. 5. dec. 21:01 UTC

Tirgus saruna

Oil Caps Positive Week on Geopolitical Turmoil -- Market Talk

2025. g. 5. dec. 20:43 UTC

Iegādes, apvienošanās, pārņemšana

Limitless CEO Siroker: Will No Longer Sell Pendant to New Customers

2025. g. 5. dec. 20:43 UTC

Iegādes, apvienošanās, pārņemšana

Limitless CEO Siroker: Existing Pendant Customers to Be Supported for at Least Another Year

2025. g. 5. dec. 20:42 UTC

Iegādes, apvienošanās, pārņemšana

Limitless CEO Dan Siroker: Limitless Has Been Acquired by Meta >META

2025. g. 5. dec. 20:01 UTC

Iegādes, apvienošanās, pārņemšana

Netflix Landed a Big Deal. Now it Could Have a Big Fight. -- WSJ

2025. g. 5. dec. 19:44 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 5. dec. 19:44 UTC

Tirgus saruna

Canada Dollar Gains Nearly 1% on Jobs Data, Rate Outlook -- Market Talk

2025. g. 5. dec. 19:39 UTC

Tirgus saruna

Silver Climbs to a New Record High -- Market Talk

2025. g. 5. dec. 19:31 UTC

Iegādes, apvienošanās, pārņemšana

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

2025. g. 5. dec. 18:30 UTC

Tirgus saruna

Canada Jobless Rate Can Fall More Before Labor Slack Disappears -- Market Talk

2025. g. 5. dec. 18:28 UTC

Iegādes, apvienošanās, pārņemšana

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

2025. g. 5. dec. 18:24 UTC

Iegādes, apvienošanās, pārņemšana

AMC and IMAX Stocks Drop. Roku Rises. How the Netflix-Warner Bros. Deal Could Shake Up Entertainment. -- Barrons.com

2025. g. 5. dec. 18:20 UTC

Tirgus saruna

Baker Hughes Reports Higher U.S. Rig Count -- Market Talk

2025. g. 5. dec. 18:11 UTC

Tirgus saruna

The Tale of Two Canadian Employment Indicators -- Market Talk

2025. g. 5. dec. 17:48 UTC

Tirgus saruna

Canadian Youth Unemployment Rate Cools -- Market Talk

2025. g. 5. dec. 17:44 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Global Equities Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

ACADIA Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

13.41% augšup

Prognoze 12 mēnešiem

Vidējais 30.11 USD 13.41%

Augstākais 38 USD

Zemākais 21 USD

Pamatojoties uz 18 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi ACADIA Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

18 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 18 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam ACADIA Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

14.845 / N/AAtbalsts un pretestība

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Noskaņojums

By Acuity

19 / 374 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.